Advised on sale of specialty respiratory pharmaceutical company
Advised on sale of specialty respiratory pharmaceutical company
John and his team acted as the lead financial advisor and book runner for Adamis Pharmaceuticals, a specialty pharmaceutical company developing an EpiPen alternative for anaphylaxis and a number of respiratory drugs. Advisory services included guiding the company through the complex process of simultaneously marketing and closing a public offering and getting the company uplisted to a national stock exchange (Nasdaq Capital Market.)
Note: This work was performed prior to joining Stout.